Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey

被引：6

作者：

Grosso, Giuseppe ^{[1
]}

Rossetti, Diego ^{[1
]}

Coccolini, Federico ^{[2
]}

Bogani, Giorgio ^{[3
]}

Ansaloni, Luca ^{[2
]}

Frigerio, Luigi ^{[1
]}

机构：

[1] Papa Giovanni XXIII Hosp, Dept Gynecol & Obstet, Bergamo, Italy

[2] Papa Giovanni XXIII Hosp, Dept Surg, Bergamo, Italy

[3] Univ Insubria, Del Ponte Hosp, Dept Obstet & Gynecol, Varese, Italy

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2014年 / 290卷 / 03期

关键词：

Intraperitoneal chemotherapy; Advanced ovarian cancer; Cytoreductive surgery; HIPEC; GYNECOLOGIC-ONCOLOGY-GROUP; STAGE-III OVARIAN; INTRAVENOUS CISPLATIN; PHASE-II; CYTOREDUCTIVE SURGERY; CARCINOMA; TRIAL; CARBOPLATIN; PACLITAXEL; VOLUME;

D O I：

10.1007/s00404-014-3252-2

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Intraperitoneal chemotherapy preceded by cytoreductive surgery should be the standard of care in the treatment of advanced epithelial ovarian cancer. This combination has been extensively examined in both the clinical and preclinical settings with favourable oncologic outcomes. Unfortunately, despite the existence of these evidence-based data, this management strategy remains underutilised. We review and discuss the role of intraperitoneal chemotherapy with particular emphasis about the pharmacokinetics and pharmacodynamics aspects, the mode of administration, the reported side effects, the compliance of the patients and the clinical ongoing studies. Further studies investigating the pharmacokinetics and pharmacodynamics aspect of IP route may help to reduce toxicity pending more effective treatments.

引用

页码：425 / 434

页数：10

共 47 条

[1]

Alberts DS, 1996, NEW ENGL J MED, V354, P34

[2] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[3] The Future of Targeted Therapies in Ovarian Cancer [J].

Banerjee, Susana ;

Gore, Martin .

ONCOLOGIST, 2009, 14 (07) :706-716

[4] A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment [J].

Barakat, RR ;

Almadrones, L ;

Venkatraman, ES ;

Aghajanian, C ;

Brown, C ;

Shapiro, F ;

Curtin, JP ;

Spriggs, D .

GYNECOLOGIC ONCOLOGY, 1998, 69 (01) :17-22

[5] Structure of the intestinal peritoneum in man [J].

Baron, MA .

AMERICAN JOURNAL OF ANATOMY, 1941, 69 (03) :439-497

[6] CARCINOMA OF OVARY - A CLINICOPATHOLOGICAL STUDY OF 86 AUTOPSIED CASES WITH SPECIAL REFERENCE TO MODE OF SPREAD [J].

BERGMAN, F .

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1966, 45 (02) :211-&

[7] INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL [J].

BRALY, PS ;

BEREK, JS ;

BLESSING, JA ;

HOMESLEY, HD ;

AVERETTE, H .

GYNECOLOGIC ONCOLOGY, 1995, 56 (02) :164-168

[8] Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].

Bristow, RE ;

Tomacruz, RS ;

Armstrong, DK ;

Trimble, EL ;

Montz, FJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259

[9] Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [J].

Burger, R. A. ;

Brady, M. F. ;

Bookman, M. A. ;

Walker, J. L. ;

Homesley, H. D. ;

Fowler, J. ;

Monk, B. J. ;

Greer, B. E. ;

Boente, M. ;

Liang, S. X. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[10] Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure [J].

Dedrick, RL ;

Flessner, MF .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (07) :480-487

← 1 2 3 4 5 →